Clinical Report: Assessment of Safety and Efficacy of Lower-Dose Daratumumab

Overview

This study evaluates the safety and efficacy of a lower-dose daratumumab regimen combined with bortezomib and dexamethasone (DVd-lite) in patients with newly diagnosed monoclonal gammopathy of renal significance (MGRS).

Background

Monoclonal gammopathy of renal significance (MGRS) is characterized by renal damage due to nephrotoxic monoclonal immunoglobulin without meeting criteria for multiple myeloma. Effective treatment is crucial to reduce the monoclonal protein load and preserve renal function. Current guidelines do not provide a standardized first-line therapy for MGRS.

Data Highlights

Key Findings

• The DVd-lite regimen demonstrated an 80% hematological overall response rate.
• A 90% renal overall response rate was observed in the study cohort.
• Complete response rates for both hematological and renal categories were 60%.
• Only one patient experienced a grade 3 treatment-related adverse event.

Clinical Implications

The DVd-lite regimen may serve as a viable initial treatment option for patients with newly diagnosed MGRS, balancing efficacy with a favorable safety profile. Clinicians should consider this approach to optimize patient outcomes while minimizing adverse effects.

Conclusion

The findings from this study suggest that the DVd-lite regimen is a promising therapeutic strategy for MGRS, demonstrating significant response rates with manageable safety concerns.

Related Resources & Content

1. International Kidney and Monoclonal Gammopathy Research Group, PMC, 2021 -- The evaluation of monoclonal gammopathy of renal significance: a consensus report
2. The ASCO Post, 2025 -- Addition of Daratumumab to Treatment Regimen in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
3. The ASCO Post — Study Findings on Novel Therapies for Hematologic Malignancies
4. Blood Cancer Journal — Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
5. The ASCO Post — FDA Approves Daratumumab/VMP Combination for Newly Diagnosed Multiple Myeloma
6. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group - PMC
7. Hematologic response and kidney outcomes of monoclonal gammopathy of renal significance excluding AL amyloidosis: a report of six cases | BMC Nephrology | Springer Nature Link
8. Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis - PubMed